Overall eosinophilia during ICI therapy may predict subsequent irAEs [20], and tumor–eosinophil cross-talk (enhanced by IL-5/IL-33) is increasingly recognized as integral to both therapeutic responses and collateral immune adverse events [21,22]. This evidence concerns the gene IL33 and neoplasm.